Clinical Trial: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Anatomic Stage I Breast Cancer AJCC v8
Study Type: INTERVENTIONAL
Official Title: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Brief Summary:
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer.Paclitaxel is in a class of medications called anti-microtubule agents.It stops cancer cells from growing and dividing and may kill them.Carboplatin is in a class of medications known as platinum-containing compounds.It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than…
Read more